Medpace Holdings Inc (MEDP) Shares Fall 4.2% -- What GF Score of
Medpace Holdings Inc (MEDP) shares fell 4.2% to $598.08, within a 52-week range of $373.00 to $677.90. The stock is overvalued by 11.3% according to GF Value™, with a GF Score™ of 97/100. Insiders sold $436.7M in shares over the past year, with no purchases. The P/E ratio is 35.1x, above its 5-year median of 31.5x.
How this was made
The 30-second read
Why it matters
The article highlights a modest overvaluation and significant insider selling, suggesting short‑term downside risk.
Market read
MEDP's 4.2% drop and negative insider sentiment may influence trading decisions in the small‑cap biotech sector.
What to watch
Potential upcoming contract wins or pipeline milestones not covered in the article could offset valuation concerns.
Background
GuruFocus provides a valuation overlay and insider activity summary for MEDP.
Ticker impact
MEDP shares fell 4.2% to $598.08 amid analyst commentary that the stock is overvalued and heavy insider selling.
downward pressure as investors react to overvaluation and large insider sell‑off
Price already dropped; valuation concerns and $436.7M of insider sales suggest weak confidence.
Market effects
Limited; reflects broader caution on high‑multiple biotech/clinical‑services stocks.
U.S. market sentiment may be slightly dampened for similar small‑cap growth names.
Minimal; no cross‑border or macro impact.
Counterpoint
Some investors may view the price dip as a buying opportunity given the strong GF Score and profitability.
Key entities
- companyMedpace Holdings Inc
NASDAQ‑listed clinical‑research services provider (ticker MEDP).
